A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination with Nivolumab in Subjects with Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Infinity

Protocol Number
IPI-549-01

To Learn More Call
(201)-510-0950